Investor Relations

Agent Benefits 4

Scaling Cannabis Distribution via Schedule III Health Plans & Insurtech

Untitled design 10

Business EcoSystem

Traditional cannabis is a CapEx trap. Novus’s FinTech gateway scales natively, eliminating agricultural and retail risks.

Asset Driven

Driven by premium receivables, our actuarial strategy yields a 48%–50% quarterly gross margin via a 15,000-agent national sales network.

Valuation Method

The company uses Embedded Value (EV)—an insurance metric that enhances standard book value by combining Net Asset Value (NAV) with the present value of future profits from existing annualized contracts..

Financial Highlights

Traditional cannabis companies are capital-expenditure traps wrapped in real estate debt. Novus MedPlan completely rewrites the investment thesis. By operating as a specialized FinTech/InsureTech cannabis distribution gateway and prescription drug plan, we scale natively without agricultural, retail, or local crop risks.

BarChart 1Q 2026 This one 1

NDEV Q1 2026: Primed for Schedule III Scaling

While competitors pivot, Novus leads with a decade-old, operational carrier infrastructure.

  • +14.7% EBITDA: Scaling efficiently via a specialized carrier model.
  • +10.7% Cash: Strategic liquidity for the projected $47B market.
  • Zero Convertible Debt: No convertible notes; maximizing pure shareholder value.
  • Agent Increase 5,000+: Massive distribution reach to millions of prospective policyholders.
  • Leak Out: To deliver ironclad float protection, Novus enforces mandatory leak-out provisions for all third-party vendors. This structural guardrail systematically regulates liquidations, eliminating sudden market dumping and ensuring stabilized trading volume.

Capital Structure

As of March 31, 2026

No Toxic Debt Features

Authorized Shares:200 million
Outstanding Shares:128,803,624
Float:30,948,730
Par Value:$0.001
Restricted Shares:88,989,251
Untitled design 11

Novus Acquisition & Development Corporation (NDEV), operating as Novus Cannabis MedPlan®, has pioneered health insurance that covers both THC/CBD cannabis and traditional prescription drugs since 2015. This proprietary dual-coverage structure provides a financial moat, ensuring stable, recurring revenue for Novus and its in-network providers.

Revenue is generated from insurance premiums, giving policyholders access to medications via an online distribution platform. NDEV has a national reach through 15,000 agents/brokers and over 200 dispensaries.

pdf icon 50x50 1
pdf icon 50x50 1
pdf icon 50x50 1
pdf icon 50x50 1
pdf icon 50x50 1
pdf icon 50x50 1
pdf icon 50x50 1
Press Release Icon 3/3/2026 Novus (NDEV) 2025 Annual Report
Press Release Icon 12/17/2025 Novus (NDEV) Reports Q3 2025
Press Release Icon 11/12/2025 Novus Reports Q3 Earnings: Highlighting Self-Funded Growth and Investor Value
Press Release Icon 10/07/2025 NDEV Launches Rx/Cannabis Online Platform, Accelerates Provider Enrollment
Press Release Icon 08/12/2025 Novus Q2 2025 Reports Steady Financial Performance and Strategic Expansion
Press Release Icon 07/08/2025 Novus Reaction to the "Big Beautiful Bill"
Press Release Icon 05/12/2025 Novus’s Positive Financial Performance and Market Position Highlight Novus's 1Q 2025
Press Release Icon 03/23/2025 Novus Expands Its Reach in the Rapidly Growing Cannabis Ancillary Sector
Cap Structure
As of  March 31, 2026
Authorized Shares:200 million
Outstanding Shares:128,803,624
Float:30,948,730
Par Value:$0.001
Restricted Shares:88,989,251
Due Diligence Links 
As of  March 31, 2026
Quote:Click Here
Filings:Click Here
Pitch Deck:Click Here
Investment Highlights Video:Click Here
  

Footnotes:

  • Leak Out Vendor Shares: Third-party vendors with treasury-issued stock must sell their shares gradually based on 15% of the average daily trading volume over the past 30 days.
  • Insider Sales: No insider selling common stock for three years.
 

1. Compliance & The “Ancillary” Advantage

Novus is a non-plant-touching technology and administrative platform. Because we do not handle or profit directly from the sale of cannabis, we are not subject to IRS 280E tax restrictions. Our core product is a federally compliant Prescription Drug Program (PDP); cannabis is integrated strictly as a “value-added” discount feature, de-risking the model for institutional investors and traditional banking.

2. Employer-Centric Customization

We empower HR departments to modernize health benefits without legal exposure. Novus provides the framework for companies to align corporate values with modern wellness needs, offering a compliant structure that integrates cannabis-inclusive policies into traditional employer-sponsored health plans.

3. Novus Cannabis RX: Hybrid D2C Platform

Our Direct-to-Consumer platform bridges traditional healthcare and the cannabis industry through a “hybrid” model:

  • Traditional PDP: A robust prescription drug plan for FDA-approved medications.

  • Value-Added Access: Exclusive, pre-negotiated discounts at a nationwide network of licensed dispensaries.

  • Digital Integration: A single, professional portal for both traditional pharmacy benefits and alternative wellness.

4. Strategic Market Expansion

Novus is the primary “on-ramp” for consumers transitioning from the legacy (unregulated) market to legal, lab-tested products. By targeting the untapped employer market and partnering with national insurance brokers, the Novus MedPlan is positioned as the definitive distribution solution for the mainstreaming cannabis economy.

Federal Regulation: A Model Optimized for Growth

Strategic Positioning & Tax Efficiency: Novus is engineered to thrive within the current regulatory landscape. As a non-plant-touching technology and administrative platform, we are structurally insulated from the punitive restrictions that impact cultivators and retailers. This allows Novus to maintain standard corporate tax deductions and a healthy, scalable bottom line.

Institutional-Grade Compliance: We operate as a “grown-up” player in the space, prioritizing rigorous adherence to federal financial standards. Novus maintains strict Anti-Money Laundering (AML) and Bank Secrecy Act (BSA) protocols. This commitment to high-level compliance ensures we remain “institutional-ready,” safeguarding our relationships with traditional banking partners and enterprise-level clients.

Legislative Catalysts as Growth Drivers: Rather than remaining unaffected by federal shifts, Novus is positioned to catch the wave of industry evolution. We view Cannabis Rescheduling (Schedule III) and the SAFER Banking Act as massive growth tailwinds. These milestones will lower the barrier for entry for Fortune 500 employers, triggering a surge in demand for the compliant, turnkey benefit solutions that only Novus provides.

Interstate Scalability: By utilizing a state-regulated insurance framework and a federally compliant Prescription Drug Program (PDP), Novus can scale efficiently across legal jurisdictions. We provide a federally defensible bridge between traditional healthcare and the cannabis industry, offering stability in an evolving market.

Contact Us

* Indicates Required Field

855-228-7355

We are available Monday - Friday 9:00 am - 5:00 pm (EST) Email: info@getnovusnow.com

MEMBERS
SUBSCRIBE TO NEWSLETTER
CALL US

855-228-7355

EMAIL US

info@getnovusnow.com

An affiliate can only market to states where Novus MedPlan is licensed. Providers and Members can only sign up in states where Novus MedPlan is licensed. Any technical issues, please contact info@getnovusnow.com. Copyrights © 2026 Novus Acquisition & Dev. All rights reserved
Novus Cannabis MedPlan
Logo

Check Zip Code Availability

We found a match!

Shopping cart